Resmed Inc. Stock
Price
Target price
€202.10
€202.10
0.640%
1.3
0.640%
€256.90
13.03.26 / Tradegate
WKN: 895878 / Symbol: RMD / Name: ResMed / Stock / Healthcare Equipment & Supplies / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Resmed Inc. Stock
Resmed Inc. gained 0.640% compared to yesterday.
Resmed Inc. is currently one of the favorites of our community with 20 Buy predictions and no Sell predictions.
As a result the target price of 256 € shows a positive potential of 26.67% compared to the current price of 202.1 € for Resmed Inc..
Pros and Cons of Resmed Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Resmed Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Resmed Inc. | 0.640% | -7.251% | -4.984% | -0.148% | -3.070% | 5.118% | 30.387% |
| Veeva Systems A | -0.380% | -7.092% | 6.751% | -25.488% | -18.251% | -0.641% | -27.406% |
| Thermo Fisher Scientific Inc. | -1.510% | -5.677% | -4.069% | -13.083% | -17.463% | -19.228% | 8.340% |
| Intuitive Surgical Inc | -0.530% | -2.000% | 1.210% | -6.016% | -15.363% | 95.007% | 102.280% |
Comments
ResMed (NYSE:RMD) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Show more
Ratings data for RMD provided by MarketBeat
ResMed (NYSE:RMD) had its "overweight" rating reaffirmed by analysts at KeyCorp.
Show more
Ratings data for RMD provided by MarketBeat
ResMed (NYSE:RMD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Show more
Ratings data for RMD provided by MarketBeat
News
Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?
ResMed (NYSE: RMD) finds itself in an investment limbo as revolutionary weight loss drugs create both immediate opportunities and long-term existential questions for the sleep apnea device maker.
